Division of Vascular and Endovascular Surgery, Center for Vascular Biology Research and the Transplant Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Transplantation. 2012 Feb 27;93(4):373-82. doi: 10.1097/TP.0b013e3182419829.
Transplant arteriosclerosis (TA) is the pathognomonic feature of chronic rejection, the primary cause of allograft failure. We have shown that the NF-κB inhibitory protein A20 exerts vasculoprotective effects in endothelial and smooth muscle cells (SMC), and hence is a candidate to prevent TA. We sought direct proof for this hypothesis.
Fully mismatched, C57BL/6 (H2) into BALB/c (H2), aorta to carotid allografts were preperfused with saline, recombinant A20 adenovirus (rAd.A20) or rAd.β-galactosidase (β-gal), implanted, harvested 4 weeks after transplantation, and analyzed by histology, immunohistochemistry, and immunofluorescence staining. We measured indoleamine 2,3-dioxygenase, interleukin-6, and transforming growth factor-β mRNA and protein levels in nontransduced, and rAd.A20 or rAd.β-gal-transduced human SMC cultures after cytokine treatment.
Vascular overexpression of A20 significantly reduced TA lesions. This correlated with decreased graft inflammation and increased apoptosis of neointimal SMC. Paradoxically, T-cell infiltrates increased in A20-expressing allografts, including the immunoprivileged media, which related to A20 preventing indoleamine 2,3-dioxygenase upregulation in SMC. However, infiltrating T cells were predominantly T-regulatory cells (CD25+/Forkhead Box P3 [FoxP3+]). This agrees with A20 inhibiting interleukin-6 and promoting transforming growth factor-β production by medial SMC and in SMC cultures exposed to cytokines, which favors differentiation of regulatory over pathogenic T cells.
In summary, A20 prevents immune-mediated remodeling of vascular allografts, therefore reduces TA lesions by affecting apoptotic and inflammatory signals and modifying the local cytokine milieu to promote an immunoregulatory response within the vessel wall. This highlights a novel function for A20 in local immunosurveillance, which added to its vasculoprotective effects, supports its therapeutic promise in TA.
移植动脉硬化(TA)是慢性排斥反应的特征性表现,也是同种异体移植物失功的主要原因。我们已经证明,NF-κB 抑制蛋白 A20 在血管内皮细胞和血管平滑肌细胞(SMC)中发挥血管保护作用,因此是预防 TA 的候选药物。我们试图为此假说提供直接证据。
对完全错配的 C57BL/6(H2)到 BALB/c(H2)主动脉至颈动脉同种异体移植物进行盐水、重组 A20 腺病毒(rAd.A20)或 rAd.β-半乳糖苷酶(β-gal)预灌注,植入,在移植后 4 周收获,并进行组织学、免疫组织化学和免疫荧光染色分析。我们测量了非转导和 rAd.A20 或 rAd.β-gal 转导的人 SMC 培养物在细胞因子处理后吲哚胺 2,3-双加氧酶、白细胞介素 6 和转化生长因子-β mRNA 和蛋白水平。
血管过表达 A20 可显著减少 TA 病变。这与移植物炎症减少和内膜 SMC 凋亡增加相关。矛盾的是,A20 表达的同种异体移植物中 T 细胞浸润增加,包括免疫特权的中膜,这与 A20 防止 SMC 中吲哚胺 2,3-双加氧酶上调有关。然而,浸润的 T 细胞主要是 T 调节细胞(CD25+/Forkhead Box P3 [FoxP3+])。这与 A20 抑制白细胞介素 6 并促进中膜 SMC 产生转化生长因子-β以及在暴露于细胞因子的 SMC 培养物中一致,这有利于调节性 T 细胞而非致病性 T 细胞的分化。
综上所述,A20 可防止血管同种异体移植物的免疫介导重塑,从而通过影响凋亡和炎症信号以及改变局部细胞因子环境来促进血管壁内的免疫调节反应,减少 TA 病变。这突显了 A20 在局部免疫监视中的新功能,加上其血管保护作用,支持其在 TA 中的治疗前景。